STOCKHOLDERS' EQUITY (Tables)

3 Months Ended

Mar. 31, 2024

STOCKHOLDERS' EQUITY

Schedule of transaction and other information relating to stock options

				Weighted-Average
				Remaining	Aggregate
	Number of	Weighted-Average		Contractual Term	Intrinsic
	Options	Exercise Price		(In Years)	Value
Outstanding at December 31, 2023	5,224,136	$	2.90	5.28	$	5,021,952
Grants	740,139		3.56	—		—
Exercised	—		—	—		—
Forfeited/cancelled/expired/settled	—		—	—		—
Outstanding at March 31, 2024(1)	5,964,275		2.99	5.62	$	377,161
Vested and expected to vest at March 31, 2024	5,909,679		2.97	5.59		377,161
Unvested at March 31, 2024	468,035		4.61	8.98		—
Exercisable at March 31, 2024	5,496,240		2.85	5.33		377,161

(1)   The aggregate intrinsic value in the table above represents the difference between the Company’s stock closing price on the last day of trading during the three months ended March 31, 2024, and the exercise price, multiplied by the number of shares that would have been received by the holders of in-the-money options had all the option holders exercised their options on March 31, 2024. This amount changes based on the fair market value of the Company’s stock.

Schedule of transaction and other information relating to restricted stock grants

		Average
		Fair Value
		at Grant
	Shares	Date
Unvested at December 31, 2023	313,117	$	4.77
Grants	1,190,382		3.48
Vested	(1,087,979)		3.50
Forfeited/cancelled/expired	—		—
Unvested at March 31, 2024	415,520	$	4.39